Jump to content
Main menu
Main menu
move to sidebar
hide
Navigation
Main Page
My Profile
My Assessments
My Life Story
Med Classes
Problems
Recent changes
Pharmacopedia
Search
Search
Appearance
Create account
Log in
Personal tools
Create account
Log in
Drilldown: Medicines
English
Tools
Tools
move to sidebar
hide
Actions
General
Printable version
Appearance
move to sidebar
hide
Choose a table:
Medicines (732)
Medicines
> starting dose:
No current medical indication. Historical anesthetic dose 0.25 mg/kg IV (Sernyl).
&
routes:
IM
&
bioavailability:
~72% oral; ~85% smoked'"`UNIQ--ref-00000066-QINU`"'
Use the filters below to narrow your results.
generic:
Phencyclidine (1)
brand:
Sernyl (human, withdrawn 1965); Sernylan (veterinary, withdrawn 1978) (1)
classes:
[[:Category:Anesthetics|Anesthetic (historical)]] (1)
·
[[:Category:Arylcyclohexylamines|Arylcyclohexylamine]] (1)
·
[[:Category:Dissociatives|Dissociative]] (1)
·
[[:Category:NMDA_receptor_antagonists|NMDA receptor antagonist]] (1)
·
[[:Category:Sigma-1_receptor_agonists|Sigma-1 receptor agonist]] (1)
mechanism:
None
(1)
uses:
'"`UNIQ--vote-00000063-QINU`"', '"`UNIQ--vote-00000064-QINU`"' (1)
starting dose:
(Click arrow to add another value)
None
·
~10 units SC at the same time daily, or 0.1-0.2 units/kg/d; titrate by fasting glucose
·
'''5 mg PO at bedtime for women, 5-10 mg for men''' (per FDA's 2013 sex-specific dose reduction for women due to slower clearance). Ambien CR 6.25 mg women / 6.25-12.5 mg men. Intermezzo SL 1.75 mg women / 3.5 mg men
·
0.25 mg
·
0.4 mg PO daily (general prevention); 0.8-1 mg/d in pregnancy; 4 mg/d for women with prior NTD-affected pregnancy; 1 mg/d during methotrexate therapy
·
0.4 mg PO once daily, 30 minutes after the same meal each day
·
0.5 mg PO once daily
·
0.5-1 mg PO/IV once or twice daily; titrate to clinical response. Approximate equipotency: bumetanide 1 mg ≈ furosemide 40 mg ≈ torsemide 20 mg
·
0.5-2 mg/kg/d divided or single morning dose for acute conditions; lowest effective dose for chronic conditions, with planned taper
·
0.5-3 mg PO 30-60 minutes before bedtime. Some patients respond to micro-doses (0.3 mg) without additional benefit at higher doses. For circadian phase shifting, timing relative to dim-light melatonin onset matters more than absolute dose
·
0.5–1 oz (10–30 g) ground for psychoactive effect; far smaller for culinary use
·
0.75 mg SC weekly'"`UNIQ--ref-00000053-QINU`"'
·
1 capsule (20/10 mg dextromethorphan/quinidine) PO once daily × 7 days, then 1 capsule BID
·
1 drop in affected eye(s) TID (monotherapy); BID with timolol (Cosopt)
·
1 drop in the affected eye(s) once daily in the evening
·
1 drop in the affected eye(s) once daily in the evening (Lumigan); Latisse applied to upper lash line at bedtime
·
1 g PO QID on an empty stomach (1 hour before meals and at bedtime); 1 g BID for maintenance
·
1 mg at bedtime (PTSD nightmares); 1 mg BID–TID (HTN)
·
1 mg PO at bedtime to limit first-dose syncope; titrate weekly to 5-10 mg
·
1 mg PO once daily
Other values:
1 tablet (4.8355 mg oxycodone / 325 mg aspirin) PO every 6 hours as needed
1 tablet (85/500 mg sumatriptan/naproxen) PO at migraine onset; may repeat after 2 hours if needed; maximum 2 tablets per 24 hours
1 tablet (dextromethorphan 45 mg / bupropion 105 mg) PO daily × 3 days, then increase to 1 tablet BID
1-2 capsules (50 mg butalbital / 325 mg acetaminophen / 40 mg caffeine each) PO every 4 hours as needed; maximum 6 capsules/d
1-2 capsules (50 mg butalbital / 325 mg aspirin / 40 mg caffeine each) PO every 4 hours as needed; maximum 6 capsules/d
1-2 mg PO once daily with breakfast; titrate by glycemic response
1-2 tablets (15-60 mg codeine, 300-600 mg acetaminophen) PO every 4-6 hours as needed
1.6 mcg/kg/d in young healthy adults; 25-50 mcg/d in elderly or cardiac disease, titrated by TSH at 6-8 weeks
10 mg
10 mg (one spray) intranasally in one nostril
10 mg PO 30 min before bedtime (with ≥7 hours of sleep planned)
10 mg PO once daily
10 mg PO once daily (5 mg if on a diuretic); titrate to 40 mg
10 mg PO once daily (5 mg in older adults or if sedation occurs)
10 mg PO once daily in the evening (adults); 4-5 mg in children
10 mg PO once daily in the morning; 5 mg starting in heart failure
10 mg PO once daily in the morning; may titrate to 25 mg for additional glycemic effect
10 mg PO once daily × 7 days, then 20 mg × 7 days, then 40 mg as target dose (take with food)
10 mg PO once daily, with or without food
10 mg PO once daily; may increase to 20 mg as tolerated, or decrease to 5 mg if needed
10 mg PO once daily; titrate to 20 mg/day after 1-2 weeks if needed
10 mg PO/IV/IM QID, '''not to exceed 12 weeks''' (tardive dyskinesia risk); intranasal Gimoti 15 mg BID
10 mg PRN; 2.5–5 mg daily for continuous coverage / BPH
10 mg ~1 h before sexual activity
10 mg/kg IV every 2 weeks
10-20 mEq PO daily for prevention; treat established hypokalemia per measured deficit, typically 40-100 mEq/d in divided doses; IV 10 mEq/h peripheral, 20 mEq/h central with telemetry
10-20 mg PO once daily
10-20 mg PO once daily (5 mg in Asian ancestry, elderly, hypothyroidism, or strong CYP/SLCO1B1 interactions)
10-20 mg PO once daily in the evening (40 mg starting allowed for high CV risk)
10-20 mg PO/IV once daily; titrate by clinical response. 1:1 IV to PO conversion (unlike furosemide's 1:2)
10-40 mg PO daily depending on hyperthyroidism severity; titrate by clinical and biochemical response (target TSH/free T4)
100 mg IV every 3 months; may increase to 300 mg IV every 3 months
100 mg PO BID × 5 days (Macrobid) for cystitis; 50-100 mg HS for chronic prophylaxis
100 mg PO BID; rickettsial 200 mg/d; doxy-PEP 200 mg within 72 hours after condomless sex
100 mg PO once daily (50 mg if CrCl 30-44; 25 mg if <30 or dialysis)
100 mg PO once daily; titrate by 100 mg every 2-4 weeks to a serum urate target (typically <6 mg/dL, or <5 in tophaceous disease)
100 mg at bedtime daily
100 mg ~15 min before sexual activity
100-200 mg PO TID (max 600 mg/d)
100-200 mg PO TID after meals × no more than 2 days when used with concurrent antibiotic
100-200 mg PO once or twice daily; pediatric weight-based
1000 mg PO once daily; 500-2000 mg/d in single or divided doses
10–40 mg (situational anxiety); 40 mg BID (HTN)
12.5-25 mg PO once daily
12.5-25 mg PO once daily; titrate to 50 mg
140 mg SC every 2 weeks OR 420 mg SC monthly (3 consecutive injections 5 minutes apart due to volume)
145 mcg PO once daily for chronic idiopathic constipation; 290 mcg daily for IBS-C; pediatric 72 mcg daily
15 mg PO at bedtime, titrate to 30-45 mg/day after 1-2 weeks. '''Counterintuitive dose paradox''': lower doses (7.5-15 mg) are more sedating than higher doses because H1 antihistamine effect dominates at low dose
15-30 mg PO once daily; titrate to 45 mg
15-37.5 mg PO once daily before breakfast or 1-2 hours after; Lomaira 8 mg TID
150 mg PO once daily; titrate to 300 mg if needed
18 mcg DPI once daily (HandiHaler); 2.5 mcg per actuation × 2 inhalations once daily (Respimat)
2 g PO BID with meals (4 g/d total)
2 mg PO every 6-8 hours; titrate by 2-4 mg per dose every 1-4 days; maximum single dose 16 mg, maximum daily dose 36 mg
2 tablets (75 mg tramadol / 650 mg acetaminophen) PO every 4-6 hours as needed; maximum 8 tablets/day for ≤5 days
2.25 g at bedtime + 2.25 g 2.5–4 h later; titrate weekly to 6–9 g/night total
2.5 mg IR, 5 mg XR, or 12.5mg Mydayis
2.5 mg PO once daily (1.25 mg in CHF or volume depletion); titrate to 5-10 mg/d
2.5 mg SC weekly × 4 wk (non-therapeutic ramp)'"`UNIQ--ref-000002FB-QINU`"'
2.5-5 mg PO once daily; titrate to 10 mg/d
2.5–5 mg daily (HTN); 1.25 mg daily (HFrEF, slow titration)
20 mg PO QID (start 10 mg and titrate); IM 20 mg q6h short-term
20 mg PO once daily 30-60 minutes before breakfast
20 mg PO once daily with the evening meal; titrate to 40-80 mg/d
20 mg PO once daily; titrate to 40 mg/d after 2 weeks if needed
20 mg PO once daily; titrate to 40 mg/day after 1 week if tolerated. Elderly (>60) and hepatic impairment: 20 mg/day ceiling
20 mg PO twice daily, or 40 mg at bedtime
20-40 mg PO once daily, 30-60 minutes before breakfast
20-40 mg PO/IV; titrate by clinical response. In diuretic-resistant heart failure or CKD, doses to 200 mg or higher may be needed
200-400 mg PO daily; '''dose by actual body weight ≤5 mg/kg/d''' to reduce retinopathy risk (AAO 2016 guideline)
200-400 mg PO every 4-6 hours as needed. OTC max 1200 mg/day without provider direction; prescription max 3200 mg/day divided
200-400 mg PO q4h (IR); 600-1200 mg PO q12h (Mucinex 12-Hour ER)
225 mg SC monthly, or 675 mg SC every 3 months (quarterly)
25 mg
25 mg (schizophrenia, immediate-release); 50 mg (bipolar mania, immediate-release); 50 mg (Seroquel XR, schizophrenia or bipolar)
25 mg PO at bedtime (no titration); may increase to 50 mg if 25 mg inadequate
25 mg PO once daily for HFrEF and primary aldosteronism; up to 100 mg/d for ascites; 50-200 mg/d for hirsutism
25 mg PO once daily; titrate to 50 mg after 4-8 weeks if needed
25-50 mg PO once daily; titrate to 100 mg/day
250-500 mg PO BID × 7-14 days; IV 1.5 g q8h for serious infections
250-500 mg PO QID; 7.5-12.5 mg/kg IV q6h; topical and ophthalmic per formulation
250-500 mg PO every 6-8 hours
25–50 mg BID (tartrate); 25–100 mg daily (succinate); 12.5 mg daily in HFrEF
30 mg PO daily (1/2 grain); titrate by TSH at 6-8 weeks; 60 mg desiccated thyroid is approximately equivalent to 88-100 mcg levothyroxine
300 mg PO BID, or 600 mg PO once daily, ×5-10 days; pediatric 14 mg/kg/d
300 mg PO at bedtime night 1, 300 mg BID day 2, 300 mg TID day 3; titrate to clinical effect, commonly 1800-3600 mg/day divided TID
325 mg PO daily to TID (=65 mg elemental iron/tablet); alternate-day dosing is now favored by hepcidin physiology for better absorption with less GI burden
325-1000 mg PO every 4-6 hours as needed; maximum 4 g/d in healthy adults, 3 g/d in regular users or hepatic risk; pediatric 10-15 mg/kg every 4-6 hours
34 mg PO once daily
4 L oral solution (GoLYTELY-class) split-dose: 2 L evening before, 2 L morning of procedure; low-volume products (MoviPrep, Plenvu) use 1-2 L with required clear-fluid intake
4 g PO daily (as 4 x 1 g capsules once daily, or 2 capsules BID)
4 mg PO initially, then 2 mg after each loose stool, '''not to exceed 16 mg/d''' (8 mg OTC); chronic-use lower
4-8 mg PO or IV every 8 hours as needed; 16 mg single dose preoperatively for PONV prevention
40 mg PO once daily (10-20 mg in elderly, hepatic impairment, or strong drug interactions)
40 mg PO once daily; titrate to 80 mg
40 mg PO or IV once daily
40 mg SC every other week (most adult indications); IBD induction 160 mg week 0, 80 mg week 2, then 40 mg every other week
400 mg PO/IV once daily
42 mg PO once daily with food (no titration)
5 mg / 325 mg PO every 4-6 hours as needed; total acetaminophen <3 g/d
5 mg PO
5 mg PO TID or 7.5 mg PO BID; titrate by 5 mg every 2-3 days to clinical effect, commonly 30-60 mg/day divided BID-TID
5 mg PO at bedtime; may increase to 10 mg if inadequate
5 mg PO daily for BPH; 1 mg PO daily for androgenetic alopecia
5 mg PO once daily (no renal dose adjustment, unlike sitagliptin)
5 mg PO once daily at bedtime; titrate to 10 mg/day after 4-6 weeks. Severe Alzheimer disease: may escalate to 23 mg/day. Adlarity patch: 5 or 10 mg/day applied weekly
5 mg PO once daily in the evening
5 mg PO once daily, 30 minutes before breakfast; XL: 5 mg with breakfast
5 mg PO once daily; titrate by 5 mg weekly to target 10 mg PO BID. XR formulation: 7 mg/day, titrate to 28 mg/day
5 mg PO once daily; titrate to 10 mg after 2 weeks if needed
5 mg daily
5-10 mg PO at migraine onset; may repeat after 2 hours, maximum 30 mg/24 hours
5-10 mg PO once daily (2.5 mg if on diuretic or in heart failure); titrate to 10-20 mg BID for HFrEF
5-10 mg PO once daily (2.5 mg in heart failure, hyponatremia, or volume depletion)
5-15 mg PO once at bedtime; 10 mg PR for faster effect; bowel prep regimens use higher single doses
50 mg PO BID; titrate to 100-200 mg BID; pill-in-pocket 200-300 mg PO single dose for AF conversion
50 mg PO at bedtime; titrate by 50 mg every 4-7 days to clinical effect. Total daily doses >100 mg divided BID. Luvox CR: 100 mg PO once daily, may titrate to 300 mg/day
50 mg PO daily (25 mg in volume depletion or hepatic impairment)
50 mg PO once daily ('''no titration required''', distinguishing it favorably from venlafaxine)
50 mg PO once daily with fatty food in the evening × 14 days
50 mg ~1 h before sexual activity (ED); 20 mg TID (PAH)
500 mg PO TID or 875 mg PO BID for most indications; 80-90 mg/kg/d divided BID in pediatric otitis media
500 mg PO TID × 7-10 days (most indications); 2 g single dose for trichomoniasis; 500 mg IV q8h for severe anaerobic infection; rectal 1 g BID
500 mg PO day 1, then 250 mg PO daily days 2-5 (Z-Pak); 1 g PO single dose for chlamydia; pediatric dosing 10 mg/kg day 1, 5 mg/kg days 2-5
500 mg PO every 6 hours, or 250 mg every 6 hours for mild infections
500 mg PO once or twice daily with meals; titrate weekly to limit GI effects
500-750 mg PO BID; 400 mg IV q8-12h
500-750 mg PO/IV once daily
6/25 mg PO once daily in the evening; titrate within range 3/25 to 18/75 mg by clinical response and tolerability
60 mg PO BID or 180 mg PO once daily
7.5 mg PO once daily; titrate to 15 mg daily if needed. Vivlodex 5 mg PO once daily, max 10 mg
70 mg SC monthly; may increase to 140 mg monthly
700 mg IV q4w × 3 doses, then 1400 mg IV q4w; may discontinue when amyloid PET shows clearance
75 mg PO once daily for maintenance; 300-600 mg PO loading dose in ACS or before PCI
80-160 mg PO once daily (40 mg BID in HFrEF, titrating up to 160 mg BID)
A ''marduuf'' bundle (~50 g fresh leaves) chewed over a couple of hours
A measured pour of absinthe diluted 5:1 with cold water over sugar (the louche ritual)
ACS/PCI: 180 mg PO loading dose, then 90 mg PO BID for 12 months; long-term post-MI: 60 mg BID
ADHD (Kapvay ER): 0.1 mg PO at bedtime, titrate weekly to 0.4 mg/day divided BID. HTN (IR): 0.1 mg PO BID, titrate by 0.1 mg increments
ADHD: 30 mg PO once daily in the morning; titrate by 10-20 mg weekly to clinical effect. Binge-eating disorder: 30 mg/day, titrate to 50-70 mg/day
Active UC: Lialda 2.4-4.8 g PO once daily, Apriso 1.5 g PO once daily; maintenance 1.2-2.4 g/d; rectal Rowasa enema 4 g HS for distal disease; Canasa 1 g suppository HS for proctitis
Acute gout: 1.2 mg PO at first symptom, then 0.6 mg 1 hour later (total 1.8 mg in 1 hour, the FDA-revised regimen); prophylaxis 0.6 mg PO daily or BID; FMF 1-2 mg/d; pericarditis 0.5-0.6 mg BID for 3 months; Lodoco 0.5 mg PO daily for CV risk reduction
Acute gout: 50 mg PO TID until symptom relief, then taper; maximum 200 mg/day for 3-5 days. Rheumatoid arthritis / osteoarthritis: 25-50 mg PO BID-TID. Patent ductus arteriosus: 0.2 mg/kg IV, then 0.1-0.2 mg/kg every 12-24 hours for 2 doses
Acute migraine: 75 mg PO at onset, maximum one dose per 24 hours. Preventive: 75 mg PO every other day
Adult monotherapy: 300 mg PO BID, titrate by 300 mg every 3 days. Pediatric: weight-based titration starting 8-10 mg/kg/day divided BID
Adult: 15–60 mg every 4 hours as needed.
Adult: 500 mg PO BID, titrate by 1000 mg/day every 2 weeks. Pediatric: 10-20 mg/kg/day divided BID, weight-titrated
Allergy: 25 mg PO BID-QID. Nausea/vomiting: 12.5-25 mg PO/IM/IV/PR every 4-6 hours. Motion sickness: 25 mg PO 30-60 minutes before travel. '''Pediatric <2 years: contraindicated'''
Allergy: 25-50 mg PO every 4-6 hours. Insomnia: 25-50 mg PO at bedtime. IV (acute dystonia, severe allergic reaction): 25-50 mg slow IV push
Allergy: 4 mg PO TID. Serotonin syndrome: 12 mg loading dose PO or by nasogastric tube, then 2 mg every 2 hours until clinical improvement. Appetite stimulation: 2-4 mg PO TID-QID
Anaphylaxis IM 0.3-0.5 mg (adult) into lateral thigh, repeat q5-15 minutes prn; pediatric 0.01 mg/kg IM (max 0.3 mg, max 0.5 mg in adolescents); cardiac arrest 1 mg IV/IO q3-5 minutes; severe asthma neb 0.1 mg/kg up to 5 mg; never IV bolus for anaphylaxis outside critical care
Antenatal: Celestone Soluspan 12 mg IM q24h × 2 doses; topical: pea-sized amount BID; intra-articular varies by joint
Antiplatelet: 81 mg PO once daily. Acute MI/stroke: 162-325 mg chewed. Analgesic: 325-650 mg PO every 4-6 hours as needed
Anxiety: 0.25 mg PO BID, titrate by 0.125-0.25 mg every 3 days to target 1-4 mg/day divided. Seizures: 1.5 mg/day divided TID, titrate by 0.5-1 mg every 3 days
Anxiety: 0.5-1 mg PO BID-TID. Insomnia: 1-2 mg PO at bedtime. Status epilepticus: 4 mg IV (adult), repeat after 5-10 minutes if needed. Acute agitation: 1-2 mg IM
Anxiety: 2-10 mg PO 2-4 times daily. Alcohol withdrawal: 10-20 mg PO/IV every 4-6 hours, symptom-triggered. Status epilepticus: 5-10 mg IV. Breakthrough seizures: Diastat rectal 0.2-0.5 mg/kg or Valtoco intranasal 5-20 mg
Anxiety: 25-50 mg PO QID. Pruritus: 25 mg PO TID-QID. Insomnia: 25-50 mg PO at bedtime. Pediatric: 50-100 mg/day divided
Apply a thin film to affected area BID; '''limit to 2 weeks''' continuous use and ≤50 g/week (cream/ointment); ≤50 mL/week (foam/solution); avoid face, intertriginous areas
Apply thin layer to hyperpigmented areas BID; limit to 4-6 month courses to avoid ochronosis
Byetta: 5 µg SC twice daily, within 60 min before morning and evening meals'"`UNIQ--ref-000000E3-QINU`"' · Bydureon BCise: 2 mg SC once weekly'"`UNIQ--ref-000000E4-QINU`"'
Children ≤70 kg: 0.5 mg/kg/day, titrate to 1.2 mg/kg/day after 3 days. Adults and children >70 kg: 40 mg PO once daily for 3 days, then 80 mg/day, then if needed 100 mg/day after 2-4 weeks
Chronic migraine (PREEMPT protocol): 155 units divided across 31 sites in 7 head/neck muscle groups every 12 weeks
Constipation: 15-30 mL PO daily (titrate to 1-2 soft stools/day); hepatic encephalopathy: 20-30 g (30-45 mL) PO/PR every 1-2 hours acutely until soft stools, then BID-QID to target 2-3 soft stools/day
Constipation: 17 g (one capful) PO daily dissolved in 4-8 oz fluid; bowel prep: 4 L of PEG-electrolyte solution split-dose evening before and morning of procedure
Contraception: Depo-Provera 150 mg IM every 13 weeks; Depo-SubQ 104 mg SC every 12-13 weeks; oral cycling: 5-10 mg PO daily ×5-10 days for amenorrhea
Deficiency: 50,000 IU PO weekly for 8-12 weeks, then maintenance 800-2,000 IU/day; maintenance OTC dosing typically 800-2,000 IU/d
Depression (rarely used now): 25-75 mg PO at bedtime, titrate to 150 mg/day. Neuropathic pain / migraine prophylaxis: 10-25 mg at bedtime, titrate by 10-25 mg weekly to 50-100 mg/day. Elderly: 10 mg at bedtime (Beers-list cautions apply)
Depression: 25 mg PO TID-QID or 75 mg at bedtime, titrate to 75-150 mg/day. Neuropathic pain: 10-25 mg at bedtime, titrate to 50-100 mg/day. Elderly: 10 mg at bedtime (Beers-list cautions, though less than amitriptyline)
Depression: 25-75 mg/day to start, titrate to 75-150 mg/day at bedtime. Insomnia (Silenor): 3 mg PO 30 minutes before bedtime, max 6 mg. Topical (Prudoxin): apply to affected area every 3-4 hours
ER 180-240 mg PO once daily; IR 30 mg PO QID; IV 0.25 mg/kg over 2 min for acute rate control, then 5-15 mg/h infusion
ER 30-60 mg PO once daily; immediate-release 10 mg PO TID (now rarely used for hypertension due to reflex tachycardia)
For patients already stable on memantine 28 mg/d + donepezil 10 mg/d, switch to one capsule daily of equivalent strength
Formulation-dependent. Gels: 40–50 mg topically daily. Cypionate/enanthate IM: 50–100 mg weekly. Undecanoate IM: 750 mg q10w. Patch: 4 mg/d.
General supplementation 75-90 mg/d (RDA); scurvy treatment 100-1000 mg/d for several weeks; megadose claims unsupported
HRT cyclic: 200 mg PO HS days 1-12 of each month; continuous: 100 mg PO daily; ART luteal support 100 mg vaginal TID or 90 mg gel daily
Heart failure: 3.125 mg PO BID, doubling every 2 weeks as tolerated to target 25 mg BID (50 mg BID if >85 kg). Hypertension: 6.25 mg PO BID, titrate to 25 mg BID
Hypothyroidism: 5-25 mcg PO daily (start low, titrate slowly); myxedema coma: 5-20 mcg IV q4-12h with T4 loading
ICS Pulmicort Flexhaler 180-360 mcg BID; intranasal Rhinocort 64 mcg/spray, 1-2 sprays/nostril daily; Entocort EC 9 mg PO daily for active Crohn's; Symbicort 80/4.5 or 160/4.5 mcg, 2 puffs BID
IM: 60 mg single dose or 30 mg every 6 hours. IV: 30 mg every 6 hours. Oral (continuation only): 10-20 mg every 4-6 hours. Sprix nasal: 31.5 mg every 6-8 hours. '''Maximum 5 days total combined use'''
IR 1 mg PO at bedtime, titrate weekly; XL 4-8 mg PO daily
IR 200-400 mg PO every 6-8 hours; ER 400-1000 mg PO once daily
IR 5 mg PO BID-TID; ER 5-10 mg PO daily, titrate; transdermal patch 3.9 mg/d twice weekly (OTC)
IR 5 mg PO TID; titrate to 10 mg TID if needed. Amrix ER 15 mg PO once daily. Off-label insomnia / fibromyalgia: 5-10 mg PO at bedtime
IR 80-120 mg PO TID; ER 180-240 mg PO daily; IV 2.5-5 mg over 2 min for SVT termination (under monitoring); cluster prophylaxis up to 480-960 mg/d in divided doses
IR opioid-naive: 5-10 mg PO every 4-6 hours as needed. ER opioid-naive: '''10 mg PO every 12 hours (lowest available)'''; titrate slowly to clinical effect
IR oral 50 mg PO TID or 75 mg BID. Voltaren 1% gel: apply 2-4 g to affected area QID. Pennsaid 2%: 40 drops to knee BID. Flector patch: every 12 hours
IR oral: 15-30 mg every 4 hours as needed. ER opioid-naive: 15-30 mg every 12 hours. IV/IM/SC: 2-10 mg every 3-4 hours. Epidural / intrathecal: see surgical or palliative-care protocols
IR: 25-50 mg PO every 4-6 hours as needed, titrate as tolerated. ER: 100 mg PO once daily, titrate by 100 mg every 5 days
IR: 60 mg PO every 4-6 hours. 12-hour ER: 120 mg PO every 12 hours. 24-hour ER: 240 mg PO once daily. Pediatric: weight-based
IV: 1 mEq/kg bolus in arrest indication, then titrated to ABG and clinical status; PO: 325-2000 mg up to QID as antacid
IV: traditional 1-1.7 mg/kg q8h or extended-interval 5-7 mg/kg q24h with target-trough monitoring; inhaled CF 300 mg BID × 28 days on / 28 days off; ophthalmic 1-2 drops in affected eye(s) q4h
Indication-specific: 0.5-9 mg PO/IV daily for inflammation; 4 mg IV q6h for cerebral edema; 40 mg PO once weekly in MM; 6 mg PO/IV daily ×10 days for severe COVID-19; 0.6 mg/kg PO single dose for croup (max 16 mg)
Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site.
Induction: 2/0.5 to 4/1 mg SL once in moderate withdrawal; titrate to 12–16/3–4 mg/d by day 2–3
Infiltration: 1-2% solution; '''4.5 mg/kg ceiling without epinephrine, 7 mg/kg with epinephrine'''. IV antiarrhythmic: 1-1.5 mg/kg bolus then infusion 1-4 mg/minute. Lidoderm patch: up to 3 patches per 12 hours
Inhaled (Flovent HFA) 88 mcg BID; intranasal (Flonase) 2 sprays/nostril daily; topical (Cutivate) 0.05% cream BID
Initial genital herpes 1 g PO BID × 10 days; recurrent 500 mg BID × 3 days; suppression 500 mg-1 g PO daily; zoster 1 g TID × 7 days
Initial genital herpes 400 mg PO TID × 7-10 days; episodic 800 mg TID × 2 days; suppression 400 mg BID; herpes zoster 800 mg 5×/day × 7 days; HSV encephalitis 10 mg/kg IV q8h × 14-21 days
Insomnia (off-label): 25-50 mg PO at bedtime, titrate to effect. Depression: 150 mg/day divided BID-TID; titrate to 400 mg/day outpatient or 600 mg/day inpatient
Intranasal 0.1% or 0.15%: 1-2 sprays/nostril BID; ophthalmic 0.05%: 1 drop in each eye BID
Intranasal Nasonex 2 sprays/nostril daily (50 mcg/spray); inhaled Asmanex 220 mcg DPI 1-2 inhalations daily/BID; topical Elocon 0.1% cream daily
Intuniv ER 1 mg PO once daily; titrate by 1 mg/week as tolerated to clinical response
Isosorbide mononitrate ER: 30-60 mg PO once daily in the morning, titrate to 120-240 mg/d; isosorbide dinitrate IR: 5-20 mg PO TID with a 12-14 hour nitrate-free interval to prevent tolerance
MDD/GAD: 20 mg PO once daily. Panic disorder: 10 mg titrating to 40 mg. OCD: 20 mg titrating to 40-60 mg. CR: 25 mg/day. Brisdelle: 7.5 mg at bedtime for hot flashes
MDI 90 mcg/puff, 2 puffs q4-6h prn; nebulized 2.5 mg in 3 mL saline q4-6h
Maintenance 800-2,000 IU PO daily; deficiency replacement 50,000 IU PO weekly for 8-12 weeks then maintenance, or equivalent daily dosing 5,000-10,000 IU/d
Migraine prophylaxis: 400 mg PO daily; deficiency replacement 5-30 mg/d
Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster.
Migraine: 25 mg PO at bedtime, titrate by 25 mg weekly to target 100 mg/day divided BID. Seizures: 25-50 mg/day, titrate weekly to 200-400 mg/day divided BID
Modern clinical-trial standard: 25 mg synthesized psilocybin, single oral dose with psychological support
Motion sickness: 25-50 mg PO 1 hour before travel, repeat every 24 hours as needed. Vertigo: 25-100 mg/day divided
NVAF: 20 mg PO once daily with the evening meal (15 mg if CrCl 15-50); acute VTE: 15 mg BID for 21 days, then 20 mg daily; CAD/PAD: 2.5 mg BID with aspirin
NVAF: 5 mg PO BID (2.5 mg BID if 2 of 3: age ≥80, weight ≤60 kg, serum creatinine ≥1.5 mg/dL); acute VTE: 10 mg BID for 7 days, then 5 mg BID
Narcolepsy: 75 mg PO once daily upon awakening, titrate every 3 days. OSA: 37.5 mg PO once daily, titrate.
Nebulized 500 mcg q6-8h (or with albuterol as DuoNeb); MDI 17 mcg/puff, 2 puffs QID; nasal 0.03% or 0.06% spray BID-TID
Neuropathic pain: 75 mg PO BID, titrate to 150 mg BID after 1 week. Fibromyalgia: 75 mg PO BID, titrate to 150 mg BID. Anxiety (off-label): 75-150 mg/day divided BID-TID
Niaspan ER 500 mg PO at bedtime, titrate weekly to 1-2 g/d; flushing-protective aspirin 30-60 minutes before dose; pellagra replacement 100-500 mg/d
No current medical indication. Historical anesthetic dose 0.25 mg/kg IV (Sernyl).
No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam).
OTC dentifrice/rinse 0.05-0.5% fluoride daily; Rx 1.1% sodium fluoride toothpaste/gel daily; supplements (where local water non-fluoridated) age-titrated 0.25-1 mg/d
OTC: 220 mg PO every 8-12 hours, max 660 mg/24h. Rx: 250-500 mg PO BID. Acute gout: 750 mg loading then 250 mg every 8 hours
One cup (~40–60 mg caffeine; about half of brewed coffee)
One cup (~80–145 mg caffeine for brewed; 60–100 mg for instant)
Ophthalmic 1 drop in affected eye(s) TID; topical Mirvaso 0.33% gel applied to face daily
Ophthalmic 1 drop in each eye every 8-12 hours
Ophthalmic Pataday 0.7%: 1 drop in each eye once daily (24-hour formulation); Patanol 0.1% BID; intranasal Patanase 2 sprays/nostril BID
Ophthalmic: 1 drop 0.5% in affected eye(s) BID (or once daily for XE / Istalol). Oral hypertension: 10 mg PO BID, titrate to 60 mg/day. Migraine prophylaxis: 10 mg BID, titrate to 30 mg/day
Oral 0.25 mcg daily, titrate by serum calcium and PTH; IV in CKD 0.5-3 mcg three times weekly
Oral 1-2 mg daily; transdermal patch 0.025-0.05 mg/d twice weekly; transdermal gel 0.5-1 g/d; vaginal 10 mcg tablet twice weekly for GSM. Always combine with a progestogen in patients with an intact uterus.
Oral 200-400 mg BID; ophthalmic 1-2 drops in affected eye(s) q2-4h initially, then taper; otic 5-10 drops in affected ear BID
Oral 300-450 mg PO QID; IV 600-900 mg q8h; topical 1% solution/gel BID; vaginal 100 mg ovule × 3 days or 2% cream × 7 days
Oral load 800-1600 mg/d in divided doses for 1-3 weeks, then 600-800 mg/d for 1 month, then 200-400 mg/d maintenance; IV 150 mg over 10 min then 1 mg/min for 6 hours then 0.5 mg/min
Oral: 100 mg PO BID, titrate to 400 mg BID. IV: 20 mg over 2 minutes, repeat 40-80 mg every 10 minutes as needed (maximum cumulative 300 mg); continuous infusion 2 mg/minute
Oral: 1000-1500 mg elemental calcium/day in divided doses for supplementation; IV gluconate 1 g (4.65 mEq) over 5-10 min for hyperkalemia or symptomatic hypocalcemia
Oral: 1500 mg PO QID for 2-3 days (load), then 750-1500 mg QID maintenance. IV/IM: 1000 mg every 8 hours for acute spasm
Oral: 250 mg PO once daily × 6 weeks (fingernails) or 12 weeks (toenails); topical: cream BID × 1-2 weeks
Oral: 4-6 mL (400,000-600,000 units) suspension QID swish-and-swallow; topical: BID-QID; vaginal tablet 1 daily for 2 weeks
Oral: 5 mg PO TID, titrate by 5 mg per dose every 3 days. Intrathecal: bolus test dose, then continuous infusion via implanted pump
Oral: 50-100 mg at migraine onset, may repeat in 2 hours if needed. SC: 6 mg, may repeat in 1 hour. Nasal: 5-20 mg per nostril, may repeat in 2 hours
Osteoarthritis: 200 mg PO once daily or 100 mg BID. Rheumatoid arthritis: 100-200 mg PO BID. Acute pain: 400 mg loading, then 200 mg every 12 hours
Ozempic: 0.25 mg SC weekly × 4 wk'"`UNIQ--ref-00000245-QINU`"' · Wegovy: 0.25 mg SC weekly × 4 wk'"`UNIQ--ref-00000246-QINU`"' · Rybelsus: 3 mg PO daily × 30 d'"`UNIQ--ref-00000247-QINU`"'
PO 10 mg QID; IV 5-10 mg every 20-30 minutes for hypertensive emergency
PO Medrol Dosepak (5-day taper from 24 mg to 4 mg) is the prototypic short-course outpatient regimen; IV pulse 1 g daily for 3-5 days for MS relapse; intra-articular 4-80 mg per joint q1-5 weeks
POP: 0.35 mg PO daily continuously (no placebo week); high-dose 5 mg Aygestin for amenorrhea/endometriosis 5-10 mg/d
Parkinson disease: 0.125 mg PO TID, titrate weekly to maintenance ~1.5 mg TID. Restless legs syndrome: 0.125 mg PO 2-3 hours before bedtime, titrate to 0.5 mg/day if needed
Parkinson disease: 0.25 mg PO TID, titrate weekly. Restless legs syndrome: 0.25 mg PO 1-3 hours before bedtime, titrate to 4 mg/day if needed
Pediatric 1-2 mg/kg/d (max 60 mg) PO for asthma exacerbation; adult dosing similar to prednisone milligram-for-milligram (~1:1 potency)
Pediatric 6-11: 100 mg PO daily, titrate weekly to max 400 mg. Adolescent 12-17: 200 mg, max 400 mg. Adult: 200 mg, max 600 mg.
Physiologic replacement 15-25 mg/d divided (e.g., 10 mg AM, 5 mg noon, 5 mg afternoon); stress dose 50-100 mg IV q6-8h; adrenal crisis 100 mg IV then 50-100 mg q6h; topical 0.5-2.5% applied 2-4×/d
Replacement oxide 400-800 mg/d in divided doses (high diarrhea rate); citrate 200-400 mg/d (better tolerated, better absorbed); IV sulfate 1-2 g over 5-60 minutes for hypomagnesemia or torsades; eclampsia 4-6 g IV loading then 1-2 g/h
Replacement: 1000 mcg IM daily for 1 week, then weekly for 4 weeks, then monthly; or 1000-2000 mcg PO daily (effective even in pernicious anemia via passive diffusion); intranasal 500 mcg weekly
Replacement: 15-30 mg (22.5-45 IU) daily; NASH: 800 IU daily; AREDS-2: 400 IU daily (in combination formula)
Rheumatologic: 7.5-15 mg PO or SC '''once weekly''' (not daily — daily dosing is a recognized fatal error); folic acid 1 mg PO daily on non-MTX days; oncology dosing is far higher and indication-specific
SC 4-6 units (or 1 unit per 10-15 g carbs) at meals; titrate to postprandial glucose
SC 4-6 units (or 1 unit per 10-15 g carbs) at meals; titrate to postprandial glucose. Typical total daily dose 0.5-1 U/kg/d split between basal and prandial coverage in T1DM
SL 0.3-0.6 mg every 5 minutes up to 3 doses for acute angina (call EMS if not resolved after the third); IV infusion 5-10 mcg/min titrated; transdermal patch 0.2-0.4 mg/hr for 12-14 hours daily (nitrate-free interval prevents tolerance)
SR 150 mg PO once daily for 3 days, then 150 mg BID. XL 150 mg PO once daily for 4 days, then 300 mg once daily. Zyban (smoking cessation) 150 mg daily for 3 days, then 150 mg BID
Schizophrenia / acute mania: 5-10 mg PO once daily, target 10-15 mg/day. Acute agitation IM: 10 mg, may repeat in 2 hours. Relprevv LAI: 150-300 mg every 4 weeks after oral overlap
Schizophrenia / mania: 1 mg PO BID, titrate to 4-8 mg/day. Pediatric autism irritability: 0.25-0.5 mg/day, weight-titrated. Consta LAI: 25 mg IM every 2 weeks after oral overlap
Schizophrenia/bipolar mania: 10-15 mg PO once daily, target 15-30 mg. MDD adjunct: 2-5 mg/day, target 5-15 mg. Pediatric autism irritability: 2 mg, titrate to 5-15 mg. Maintena LAI: 400 mg IM every 4 weeks after oral overlap
Schizophrenia: 1 mg PO daily × 4 days, then 2 mg daily × 3 days, then 4 mg daily. MDD adjunct: 0.5-1 mg daily, increase to 2 mg max. AD agitation: 0.5 mg daily, titrate to 2-3 mg daily.
Schizophrenia: 1.5 mg PO daily, increase to 1.5-6 mg as tolerated. Bipolar mania: 1.5 mg, may increase to 3-6 mg. Bipolar depression: 1.5 mg daily for 14 days, then 3 mg. MDD adjunct: 1.5 mg, may increase to 3 mg.
Seizures: 10-15 mg/kg/d divided BID-TID, titrate to therapeutic level (50-100 mcg/mL); bipolar mania: 750 mg/d divided, titrate
Seizures: 100-125 mg PO at bedtime x 3 days, then BID, then TID, escalating to 750-1500 mg/day. Essential tremor: 25-50 mg PO at bedtime, titrate slowly to 250-750 mg/day
Seizures: 200 mg PO BID, titrate by 200 mg/week to 800-1200 mg/day. Trigeminal neuralgia: 100-200 mg BID, titrate to 200-400 mg TID. Bipolar: 200 mg BID, titrate to 1600 mg/day
Single 60-hour continuous IV infusion: 30 mcg/kg/h × 4h → 60 mcg/kg/h × 20h → 90 mcg/kg/h × 28h → 60 mcg/kg/h × 4h → 30 mcg/kg/h × 4h
Strongyloides 200 mcg/kg PO single dose; scabies 200 mcg/kg PO repeated at 7-14 days; onchocerciasis 150 mcg/kg q6-12 months
Surgical scrub 4% CHG; preop skin prep 2% CHG/70% isopropyl alcohol (ChloraPrep); ICU bathing 2% CHG daily; oral rinse 0.12% 15 mL twice daily for 30 seconds
Topical 0.025-0.5% cream/ointment BID; intra-articular 5-40 mg per joint q3-6 months; intranasal Nasacort 110 mcg/spray, 2 sprays/nostril daily; oral paste 0.1% to lesion 2-3×/d
Topical 2% shampoo twice weekly for seborrheic dermatitis or tinea versicolor; oral use restricted by 2013 FDA action to indications where alternatives have failed
Topical cream/lotion BID; shampoo twice weekly; nail lacquer (Penlac) once daily for up to 48 weeks
Topical: 0.5-5% cream/solution to lesions BID × 2-4 weeks; systemic IV: regimen-specific in cancer chemotherapy
Topical: 1% cream BID × 2-4 weeks; vaginal: 1% or 2% cream nightly × 7 days, or 100/200/500 mg vaginal tablet single or 3-day regimens; troche: 10 mg PO five times daily × 2 weeks for thrush
Topical: apply small amount to affected area TID × 5-10 days; nasal: apply half the contents of a single-use tube into each nostril BID × 5 days
Topical: pea-sized amount to dry face at bedtime, building from 2-3×/week to nightly as tolerated; oral APL: 45 mg/m²/d in divided doses
Transplant: 5-10 mg/kg/d divided BID, titrated to trough levels (typically 100-300 ng/mL depending on regimen and post-transplant interval); ophthalmic Restasis 0.05% one drop BID
Treatment 70 mg PO once weekly (or 10 mg daily); prevention 35 mg weekly (or 5 mg daily); always taken first thing in the morning with a full glass of water, remaining upright for 30 minutes
Treatment: 75 mg PO BID × 5 days (adult); pediatric weight-based; prophylaxis: 75 mg PO once daily × 7-10 days
Trials use 25 mg or 50 mg PO daily
Typical 5 mg PO daily; 2.5 mg in elderly, low body weight, malnutrition, hepatic dysfunction. Genotype-guided initial dosing per CPIC/IWPC algorithms (CYP2C9, VKORC1, CYP4F2) is one of the most-established PGx applications in current practice
Varies by salt form and brand; e.g., Tricor 145 mg PO daily; reduce to 48 mg in renal impairment
Victoza: 0.6 mg SC daily × 1 wk'"`UNIQ--ref-00000181-QINU`"' · Saxenda: 0.6 mg SC daily × 1 wk'"`UNIQ--ref-00000182-QINU`"'
Volume and concentration titrated to clinical status; symptomatic hyponatremia: 3% NaCl 100-150 mL bolus, reassess
Volume titrated to clinical status; typical adult bolus 500-1000 mL, then reassess
Vulvovaginal: 150 mg PO single dose; oropharyngeal: 200 mg PO day 1, then 100 mg daily ×14 days; invasive candidiasis: 800 mg load, then 400 mg PO/IV daily; cryptococcal meningitis: 400-800 mg/d
Was 1 mg/kg IV q4w × 2, then 3 mg/kg × 2, then 6 mg/kg × 2, then 10 mg/kg q4w
Week 1: 1 tablet (8/90 mg) PO morning; week 2: 1 tablet AM + 1 PM; week 3: 2 AM + 1 PM; week 4 onward: 2 AM + 2 PM (32 mg naltrexone / 360 mg bupropion/d)
Week 1: 8.9 mg PO once daily in the morning. Week 2: 17.8 mg. Week 3+: 35.6 mg (max). Titrate as needed.
XR 37.5 mg PO once daily for 4-7 days, then 75 mg/day; titrate by 75 mg every ≥4 days to clinical effect. IR 25-37.5 mg BID-TID
~10 units SC at the same time daily, or 0.1-0.2 units/kg/d; titrate by fasting glucose. Frequently dosed BID at moderate-to-high doses
Search
preparations:
Historical: Sernyl 25 mg tablets, 10 mg/mL injection (human); Sernylan 100 mg/mL injection (veterinary). Illicit: white crystalline powder, oily liquid, "dipped" cigarettes ("wet"), tablets. (1)
fda max:
N/A (no current medical indication) (1)
routes:
(Click arrow to add another value)
None
·
Oral
·
IV
·
topical
· IM ·
intranasal
·
rectal
·
Subcutaneous
·
Topical ophthalmic
·
ophthalmic
·
intramuscular
·
intravenous
·
transdermal
·
vaginal
·
Subcutaneous (abdomen
·
sublingual
·
thigh
·
Inhaled
·
intra-articular
·
nebulized
Other values:
IA
IM (benzathine
IM (estradiol valerate
IM (not for IV)
IM (rare
IV (Revatio)
IV (aqueous crystalline); '''NEVER IV for benzathine — fatal cardiopulmonary events reported'''
IV (continuous infusion for DKA)
IV (gluconate or chloride for acute use)
IV (prednisolone sodium phosphate)
IV (rare)
IV (rarely used; same dose)
IV (with caution)
IV infusion (60 min) every 2 weeks; outpatient or infusion-center setting
IV infusion every 4 weeks
Inhalation (vaporized)
Inhaled (DPI
Inhaled (MDI
Intramuscular (PREEMPT injections for migraine)
Intranasal (under direct medical supervision)
Intravenous (continuous infusion in a REMS-certified facility)
Intravenous infusion
MI reports)
NeoProfen)
Oral (IR
Oral (IR and multiple ER)
Oral (IV form withdrawn US 2009 due to fatal toxicity reports)
Oral (buccal absorption)
Oral (buccal)
Oral (capsule whole or opened/sprinkled on applesauce)
Oral (continuation only)
Oral (leaf
Oral (must be taken in bed; effects within minutes)
Oral (prescribed)
Oral (sublingual disintegration)
Oral (swallow whole)
Oral (topical action; minimal systemic absorption)
Oral (with MAOI)
Oral; sublingual IR is discouraged (uncontrolled BP drops
PO (only formulation marketed in the US).
PR
SC
SC (less common)
Subcutaneous (never IV; not for use in insulin pumps)
Sublingual film or tablet (buccal for some)
Topical (cream
Topical (gel/patch)
buccal
buccal); refined cocaine has its own profile
cypionate)
endotracheal (legacy ACLS
epidural
epidural injection
especially in acute HE)
for severe malabsorption)
gel); oral (restricted)
infiltration
inhalation
insufflated
insulin pumps
intracardiac (historical only)
intralesional
intramuscular (LAI)
intramuscular (acute and long-acting)
intranasal sinus implant
intranasal; rectal and IV reported.
intrathecal
intrathecal (rare and controversial)
intrathecal (rare)
intrathecal (via implanted infusion pump)
intravenous (Caldolor
intravenous (PDA closure only)
intravesical
intravitreal
lingual spray
multiple ER formulations)
nasal
nebulized)
nerve block)
not preferred)
on empty stomach with ≤120 mL water
oral (APL only)
oral (enteric-coated
oral (undecanoate only)
oral ER
oral mucosal
oral paste
oral powder (Cambia for migraine)
oral rinse (do not swallow)
oral troche
oromucosal spray
otic
procaine)
rectal (enema
rectal (off-label use of injection)
rectal foam)
regional anesthesia (spinal
shampoo
smoked
smoked (extracted DMT)
soft-mist inhaler)
subcutaneous (LAI)
sublingual (dinitrate)
topical gel
topical skin
upper arm); same time each day
upper arm)'"`UNIQ--ref-00000056-QINU`"'
upper arm)'"`UNIQ--ref-000000E9-QINU`"'
upper arm)'"`UNIQ--ref-0000024E-QINU`"' · Oral (Rybelsus only
upper arm)'"`UNIQ--ref-00000300-QINU`"'
with or without food'"`UNIQ--ref-00000187-QINU`"'
≥30 min before any food/drink/other oral medicine)'"`UNIQ--ref-0000024F-QINU`"'
Search
onset:
Smoked 2-5 min; insufflated 5-15 min; oral 30-60 min; IV / IM ~5-15 min (1)
duration:
4-8 hours typical; longer at high doses; residual cognitive and perceptual effects up to 48 hours (1)
halflife:
Highly variable, 7-46 hours (mean ~21 h); lipophilic deposition in fat with delayed re-release contributes to wide range'"`UNIQ--ref-00000065-QINU`"' (1)
bioavailability:
(Click arrow to add another value)
None
·
100% (IV)
·
~100% from subcutaneous depot
·
~80% (oral)'"`UNIQ--ref-00000027-QINU`"'
·
70–90% (oral)
·
~100% (oral)'"`UNIQ--ref-0000001C-QINU`"'
·
~50% (oral)'"`UNIQ--ref-00000021-QINU`"'
·
~95%
·
'''Saturable''' via the LAT-1 amino-acid transporter, producing nonlinear pharmacokinetics: ~60% at 300 mg single dose, falling to ~35% at 1200 mg single dose'"`UNIQ--ref-0000002A-QINU`"'
·
10-20% (oral; reduced by food, calcium, antacids, PPIs, tea/coffee; enhanced by ascorbate)
·
100% (IV); essentially complete (oral)
·
100% (IV); rapidly neutralized by gastric acid (oral)
·
16-21% capsule, 25% suspension (oral; iron and antacids reduce absorption substantially)'"`UNIQ--ref-000009E5-QINU`"'
·
25 mg: ~29%; 50 mg: ~35%; food reduces absorption'"`UNIQ--ref-00000C4F-QINU`"'
·
30-40% (oral; increases with repeated dosing as gastric pH rises)'"`UNIQ--ref-000000DF-QINU`"'
·
40-45% (oral; not significantly affected by food)'"`UNIQ--ref-0000025C-QINU`"'
·
40-80% (oral); reduced by food, calcium, iron, PPIs, fiber; take fasting with water'"`UNIQ--ref-00000037-QINU`"'
·
42-58% (oral; dose-dependent)'"`UNIQ--ref-00000AEF-QINU`"'
·
50-60% (oral; decreased with food, but food given anyway for GI tolerance)'"`UNIQ--ref-00000019-QINU`"'
·
60-70% PO at low doses; saturable at high doses (parenteral routes preferred above 15-25 mg/week)'"`UNIQ--ref-000007C9-QINU`"'
Other values:
60-80% (oral)
60-80% (oral; not significantly affected by food)'"`UNIQ--ref-00000843-QINU`"'
64-90% (oral; not affected by food)'"`UNIQ--ref-00000079-QINU`"'
65-75% (oral)'"`UNIQ--ref-0000013F-QINU`"'
70-75% (oral)'"`UNIQ--ref-000007ED-QINU`"'
70-80% (oral)'"`UNIQ--ref-000002A4-QINU`"'
75-90% (oral; minimally affected by food)'"`UNIQ--ref-000001A2-QINU`"'
80-90% oral
90% (oral; food delays but does not reduce absorption)'"`UNIQ--ref-000004F3-QINU`"'
<0.1% systemic absorption (PEG 3350 is too large to absorb intact)
<1% (oral; further reduced by food, calcium, iron, antacids; hence the strict fasting/upright dosing rules)'"`UNIQ--ref-000006C4-QINU`"'
<1% oral (extensive first-pass via CYP3A4); ~30% inhaled lung deposition'"`UNIQ--ref-000001DE-QINU`"'
<3% systemic absorption (the basis of the safety and mechanism)'"`UNIQ--ref-00000F5E-QINU`"'
<5% (extensive hepatic first-pass; food enhances absorption of IR, hence the evening-meal dosing)'"`UNIQ--ref-00000808-QINU`"'
<5% (extensive hepatic first-pass; statin pharmacology is hepatocellular, not systemic)'"`UNIQ--ref-0000017B-QINU`"'
<5% systemic absorption (this is the safety basis)'"`UNIQ--ref-00000DC3-QINU`"'
>90% (oral)'"`UNIQ--ref-0000001C-QINU`"'
>90% (oral; food slows absorption and reduces peaks, hence the post-meal dosing rule)'"`UNIQ--ref-000001BD-QINU`"'
>90% (oral; not affected by food or gastric pH — a major practical advantage over itraconazole)'"`UNIQ--ref-00000A48-QINU`"'
>90% (oral; not significantly affected by food)'"`UNIQ--ref-00001120-QINU`"'
Absolute bioavailability not precisely characterized; food modestly increases exposure
Acid-labile; not effective orally (oral form available outside US as penicillin G salts but penicillin V is preferred for oral use)'"`UNIQ--ref-0000141A-QINU`"'
Adequate (food-dependent, must take with fatty meal)
Adequate oral bioavailability
Adequate oral bioavailability with extended-release formulation
Buprenorphine ~30% SL; naloxone <10% SL (intentional, inactive sublingually, matters only if injected)
Butalbital well-absorbed; aspirin 50-75%; caffeine ~100%'"`UNIQ--ref-000015B8-QINU`"'
Butalbital well-absorbed; caffeine ~100%; acetaminophen 85-98%'"`UNIQ--ref-000015A0-QINU`"'
Carbonate ~30-40% (best with food and acid); citrate ~24% (absorbable without acid; preferred in achlorhydria, PPI use, post-bariatric)
Codeine ~60% (oral); acetaminophen 85-98%'"`UNIQ--ref-00001518-QINU`"'
Essentially zero systemic absorption from oral or topical routes — the topical-action-only profile is the basis of its safety'"`UNIQ--ref-00000D18-QINU`"'
High (oral)
High (oral); not significantly affected by food'"`UNIQ--ref-00000397-QINU`"'
High (oral)'"`UNIQ--ref-00000FB5-QINU`"'
High (oral)'"`UNIQ--ref-00001051-QINU`"'
High (oral)'"`UNIQ--ref-00001165-QINU`"'
High (oral)'"`UNIQ--ref-000012A0-QINU`"'
High (oral; absorption not affected by food)'"`UNIQ--ref-00000825-QINU`"'
High (oral; food enhances)'"`UNIQ--ref-00001039-QINU`"'
High (oral; food prolongs absorption modestly)'"`UNIQ--ref-00000622-QINU`"'
High (oral; not affected by food, but typically given with the morning meal)'"`UNIQ--ref-0000027D-QINU`"'
High (oral; not significantly affected by food)'"`UNIQ--ref-00000B65-QINU`"'
High with fat-containing meal; reduced in malabsorption
Highly formulation-dependent; the goal is colonic delivery with minimal systemic exposure'"`UNIQ--ref-00000BBF-QINU`"'
Highly route-dependent: SL bypasses first-pass; oral has extensive first-pass (used only for chronic ER preparations); transdermal predictable'"`UNIQ--ref-00000C10-QINU`"'
Highly salt-dependent: citrate ~25-30%; oxide ~4% (limited and causes osmotic diarrhea); chloride ~12%
Highly variable due to saturable first-pass metabolism'"`UNIQ--ref-0000002C-QINU`"'
IM/SC ~100%; oral negligible (extensive first-pass and gut metabolism — hence the no-oral route)'"`UNIQ--ref-00000E53-QINU`"'
IV/IM ~100%; inhaled: minimal systemic; oral: negligible (not used orally for systemic infection)'"`UNIQ--ref-000010B4-QINU`"'
Improved with food'"`UNIQ--ref-00000052-QINU`"'
Increased substantially via CYP2D6 inhibition'"`UNIQ--ref-00001584-QINU`"'
Increased with food (varies by formulation; the micronized and nanocrystal forms are less food-dependent)'"`UNIQ--ref-000004AE-QINU`"'
Inhaled lung deposition with minimal systemic absorption (the basis of the favorable safety profile vs systemic antimuscarinics)'"`UNIQ--ref-00000F7C-QINU`"'
Inhaled lung deposition ~20%; systemic absorption from lung ~33%; oral component negligible'"`UNIQ--ref-000009C1-QINU`"'
Intranasal ~40% systemic; ophthalmic minimal'"`UNIQ--ref-000013B7-QINU`"'
Intranasal: <1% systemic; inhaled lung deposition with extensive first-pass clearance'"`UNIQ--ref-00000F9D-QINU`"'
Limited but adequate; take with food
Local (intramuscular)
Local action; minimal systemic effect
Low systemic absorption (enteric coating delivers drug to colon)'"`UNIQ--ref-0000106C-QINU`"'
Mononitrate ~100% (no first-pass; the principal advantage over dinitrate); dinitrate ~20%'"`UNIQ--ref-00001462-QINU`"'
Naltrexone ~5% (oral, extensive first-pass to 6β-naltrexol); bupropion ER ~87%'"`UNIQ--ref-00001569-QINU`"'
Negligible (not absorbed)'"`UNIQ--ref-00000058-QINU`"'
Negligible systemic absorption'"`UNIQ--ref-0000119D-QINU`"'
Not characterized; oral dosing once daily
Not formally characterized for the combination
Not formally characterized in humans.
Not formally established
Not formally established (high SC)
Not formally established; oral once-daily adequate
Not well characterized
Not well characterized'"`UNIQ--ref-00000019-QINU`"'
Olanzapine 60% (oral); fluoxetine high (oral)'"`UNIQ--ref-0000154E-QINU`"'
Oral bioavailability of psilocin from administered psilocybin approximately 50%
Oral bioavailability suitable for daily dosing
Oral non-undecanoate has essentially zero bioavailability (hepatic first-pass)
Oral ~1-3% via passive diffusion at high doses (independent of intrinsic factor); IM/SC ~100%
Oral ~5% (extensive first-pass to estrone and conjugates); transdermal bypasses first-pass, giving more physiologic estradiol:estrone ratio'"`UNIQ--ref-000003BB-QINU`"'
Oral ~70%; depot IM provides sustained release over weeks'"`UNIQ--ref-0000101B-QINU`"'
Oral ~90%; depot IM essentially 100% over the dosing interval'"`UNIQ--ref-00000F21-QINU`"'
Oral: very low (extensive first-pass); micronization improves uptake somewhat. Vaginal: high local effect with lower systemic levels (first-uterine-pass concentration)'"`UNIQ--ref-00000727-QINU`"'
Oxycodone 60-87%; aspirin 50-75%'"`UNIQ--ref-000014FB-QINU`"'
Rapid absorption; absolute bioavailability not formally established
Reasonable (not formally established as a percentage)
SC ~47%–65%'"`UNIQ--ref-0000005A-QINU`"'
SC ~55%'"`UNIQ--ref-0000018B-QINU`"'
SC ~65%–75%<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup>
SC ~80%<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup>
SC ~89%<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> · Oral ~0.4–1% (SNAC-enhanced)'"`UNIQ--ref-00000254-QINU`"'
Sandimmune: highly variable (~30%); Neoral microemulsion: ~50%, less variable; '''Sandimmune and Neoral are NOT bioequivalent and not interchangeable''''"`UNIQ--ref-00000A92-QINU`"'
Substantially improved with high-fat meal; take with food'"`UNIQ--ref-000013D2-QINU`"'
Sumatriptan ~15% (oral; substantial first-pass); naproxen ~95%'"`UNIQ--ref-000015D2-QINU`"'
Tablet ~100% relative to oral solution; extensive first-pass metabolism
Topical with limited but measurable systemic absorption'"`UNIQ--ref-00001219-QINU`"'
Topical with measurable systemic absorption (small CA inhibition observed clinically with chronic use)'"`UNIQ--ref-00000B0B-QINU`"'
Topical with minimal systemic absorption'"`UNIQ--ref-000011DA-QINU`"'
Topical with minimal systemic absorption'"`UNIQ--ref-0000123A-QINU`"'
Topical with minimal systemic absorption'"`UNIQ--ref-00001288-QINU`"'
Topical with variable systemic absorption depending on body site, occlusion, and skin integrity; HPA-axis suppression is documented even with brief courses to large areas'"`UNIQ--ref-0000079F-QINU`"'
Topical/intranasal: high local, low systemic; intra-articular: local depot then systemic absorption'"`UNIQ--ref-00000667-QINU`"'
Topical/oral local action with minimal systemic absorption'"`UNIQ--ref-00001399-QINU`"'
Topical: local effect on enamel; systemic supplementation has high oral bioavailability with skeletal accumulation
Topical: minimal systemic absorption (oral systemic 5-FU not used due to poor and variable absorption)'"`UNIQ--ref-000011BF-QINU`"'
Topical: minimal systemic absorption with normal skin; oral: variable, induced metabolism with repeated dosing'"`UNIQ--ref-00000BA4-QINU`"'
Topical: minimal systemic; oral: pH-dependent, requires gastric acid'"`UNIQ--ref-00000889-QINU`"'
Topical: minimal systemic; troche: ~3% systemic'"`UNIQ--ref-00000F46-QINU`"'
Topical; clinically meaningful systemic absorption can produce systemic α2 effects (somnolence, hypotension), especially in children'"`UNIQ--ref-000010D2-QINU`"'
Topical; minimal systemic absorption'"`UNIQ--ref-00000418-QINU`"'
Topical; minimal systemic absorption'"`UNIQ--ref-00000A03-QINU`"'
Topical; minimal systemic absorption'"`UNIQ--ref-00000DA2-QINU`"'
Tramadol ~75% (oral); acetaminophen 85-98%'"`UNIQ--ref-00001531-QINU`"'
Variable (oral; rapidly conjugated to active glucuronide; food does not affect)'"`UNIQ--ref-00000451-QINU`"'
Variable; reduced by food, calcium, iron, PPIs'"`UNIQ--ref-00000037-QINU`"'
~0.3% (oral; extensive first-pass via CYP3A4 and P-glycoprotein-mediated efflux at the intestinal and blood-brain barriers limit systemic and CNS exposure at therapeutic doses)'"`UNIQ--ref-00000FD3-QINU`"'
~10% inhaled reaches systemic circulation; ~50% PO'"`UNIQ--ref-0000009A-QINU`"'
~100% (oral); highly (~90%) protein-bound, with non-linear binding above therapeutic levels (free fraction matters clinically in hypoalbuminemia)'"`UNIQ--ref-0000097D-QINU`"'
~100% (oral)'"`UNIQ--ref-0000001B-QINU`"'
~100% (oral)'"`UNIQ--ref-00000020-QINU`"'
~100% (oral)'"`UNIQ--ref-00000027-QINU`"'
~100% (oral)'"`UNIQ--ref-00000706-QINU`"'
~100% (oral, but oral use is limited to continuation from parenteral)'"`UNIQ--ref-00000021-QINU`"'
~100% (oral; absorption complete)'"`UNIQ--ref-0000126F-QINU`"'
~100% (oral; food delays absorption, hence pre-meal dosing for IR)'"`UNIQ--ref-000002DA-QINU`"'
~100% (oral; near-complete absorption)'"`UNIQ--ref-00000018-QINU`"'
~100% (oral; not significantly affected by food)'"`UNIQ--ref-00000493-QINU`"'
~100% both components
~100% from subcutaneous depot (by definition of the route)
~12% (extensive metabolizers); ~96% (poor metabolizers)
~14% (extensive hepatic first-pass)'"`UNIQ--ref-0000001C-QINU`"'
~14% (oral; substantial first-pass); ~97% (subcutaneous); ~17% (nasal)'"`UNIQ--ref-00000016-QINU`"'
~15% (extensive hepatic first-pass)
~15% (oral; highly variable due to extensive and variable first-pass metabolism)'"`UNIQ--ref-00000022-QINU`"'
~17% (oral; food slightly reduces absorption)'"`UNIQ--ref-000003D6-QINU`"'
~20% (oral; hydrophilic, minimal CYP metabolism, mostly excreted unchanged in bile)'"`UNIQ--ref-000000FD-QINU`"'
~20% (oral; valacyclovir prodrug raises this to ~55%)'"`UNIQ--ref-00000910-QINU`"'
~20-35% (oral; extensive first-pass via CYP3A4 with R/S enantiomer differences)'"`UNIQ--ref-00000A6C-QINU`"'
~22–25%
~25% (extensive hepatic first-pass)
~25% (high first-pass)
~25% (oral)'"`UNIQ--ref-00000019-QINU`"'
~25% (oral, with extensive first-pass)'"`UNIQ--ref-00000023-QINU`"'
~25% (oral; extensive first-pass)'"`UNIQ--ref-0000001B-QINU`"'
~25% (oral; food does not affect absorption)'"`UNIQ--ref-0000005A-QINU`"'
~25% (oral; food reduces absorption ~40%)'"`UNIQ--ref-000004CE-QINU`"'
~25-35% (extensive first-pass), increased by food which slows absorption and reduces orthostatic risk'"`UNIQ--ref-0000001C-QINU`"'
~25-40% (oral; extensive first-pass)'"`UNIQ--ref-00000021-QINU`"'
~25-50% (oral; substantial first-pass via NAT2 acetylation, phenotype-dependent)'"`UNIQ--ref-00000688-QINU`"'
~26% (oral; prodrug hydrolyzed by intestinal esterases to active olmesartan; not affected by food)'"`UNIQ--ref-0000056D-QINU`"'
~28% (oral; food slows but does not reduce absorption)'"`UNIQ--ref-00000C33-QINU`"'
~30% (high first-pass)
~30% (oral)'"`UNIQ--ref-00000021-QINU`"'
~30% (oral)'"`UNIQ--ref-0000117D-QINU`"'
~30-65% (oral; acid-labile, hence enteric-coated formulations; food affects absorption variably)'"`UNIQ--ref-00000D3F-QINU`"'
~33%
~33% (extensive first-pass via CYP2C9 and CYP3A4)'"`UNIQ--ref-000000BD-QINU`"'
~33% (oral; fruit juices including grapefruit, orange, and apple reduce absorption substantially via OATP1A2 inhibition — distinctive interaction not seen with most other H1s)'"`UNIQ--ref-00000CCD-QINU`"'
~33-55% (IR); reduced by food'"`UNIQ--ref-0000001B-QINU`"'
~35% (oral, extensive first-pass; not used orally for systemic effect); ~100% (IV)'"`UNIQ--ref-00000021-QINU`"'
~36% (oral)'"`UNIQ--ref-00000C93-QINU`"'
~37% (oral, as axetil prodrug; food modestly improves absorption)'"`UNIQ--ref-00000FFA-QINU`"'
~37% (oral; food does not affect)'"`UNIQ--ref-00000A23-QINU`"'
~37% (oral; food reduces absorption modestly)'"`UNIQ--ref-000003FD-QINU`"'
~38% (oral; non-acidic prodrug improves GI tolerability over many other NSAIDs)'"`UNIQ--ref-000011FA-QINU`"'
~4% (extensive first-pass metabolism)'"`UNIQ--ref-0000001E-QINU`"'
~40%
~40% (oral); food and formulation substantially alter the absorption profile'"`UNIQ--ref-0000001E-QINU`"'
~40% (oral; extensive first-pass via CYP3A4)'"`UNIQ--ref-00000643-QINU`"'
~40% (oral; food does not significantly affect)'"`UNIQ--ref-00000EB3-QINU`"'
~40-60% (oral, with significant first-pass)'"`UNIQ--ref-00000027-QINU`"'
~44%
~45% (oral)'"`UNIQ--ref-00000C73-QINU`"'
~45% (oral; substantially higher than sumatriptan's ~14%)'"`UNIQ--ref-00000013-QINU`"'
~45%'"`UNIQ--ref-00000027-QINU`"'
~48% intranasal
~5% intranasal
~5-20% (extensive first-pass), highly variable between individuals'"`UNIQ--ref-00000024-QINU`"'
~50%
~50% (highly variable)
~50% (oral); systemic absorption from ophthalmic application is clinically meaningful via nasolacrimal drainage'"`UNIQ--ref-0000001C-QINU`"'
~50% (oral)'"`UNIQ--ref-00000027-QINU`"'
~50% (oral)'"`UNIQ--ref-000002C5-QINU`"'
~50% (oral; highly variable)'"`UNIQ--ref-00000CB4-QINU`"'
~50% (oral; highly variable, 10-100%, hence the standard 1:2 IV-to-PO conversion)'"`UNIQ--ref-00000223-QINU`"'
~50% (oral; not significantly affected by food)'"`UNIQ--ref-000001FC-QINU`"'
~50% (oral; reduced by buffering and enteric coating but onset clinically similar)'"`UNIQ--ref-00000028-QINU`"'
~50% (oral; substantial first-pass)'"`UNIQ--ref-00000024-QINU`"'
~50% (variable, CYP2D6-dependent for analgesic effect).
~50% IR (extensive first-pass via CYP3A4); ER products release-rate-limited'"`UNIQ--ref-0000074E-QINU`"'
~50-60% (oral; food enhances)
~50-60% (oral; substantial first-pass metabolism)'"`UNIQ--ref-0000002A-QINU`"'
~53% (oral)'"`UNIQ--ref-00000024-QINU`"'
~55% (oral)'"`UNIQ--ref-00000016-QINU`"'
~55% bioavailability of acyclovir after valacyclovir oral (vs ~20% from oral acyclovir directly)'"`UNIQ--ref-000005D7-QINU`"'
~58% (extended-release); ~80% (immediate-release)'"`UNIQ--ref-00000021-QINU`"'
~6% IR oral (substantial first-pass to active N-desethyl metabolite, which contributes most of the antimuscarinic adverse effects); transdermal bypasses first-pass and is better tolerated'"`UNIQ--ref-000006E2-QINU`"'
~6-13% inhaled lung deposition; ~10% oral (Entocort EC; extensive first-pass via CYP3A4 — this is the basis of the favorable hepatic-targeted local-effect profile in IBD)'"`UNIQ--ref-000009A6-QINU`"'
~60%
~60% (oral); ~100% (IM)'"`UNIQ--ref-00000027-QINU`"'
~60% (oral)'"`UNIQ--ref-00000379-QINU`"'
~60% (oral)'"`UNIQ--ref-00000D5A-QINU`"'
~60% (oral; food does not affect absorption)'"`UNIQ--ref-00000B85-QINU`"'
~60% (oral; phenoxymethyl modification makes it acid-stable, unlike penicillin G which is destroyed by gastric acid)'"`UNIQ--ref-00000E77-QINU`"'
~60% (oral; substantially increased with high-fat meal)'"`UNIQ--ref-00001093-QINU`"'
~60% from subcutaneous depot (reduced by reversible albumin binding via the myristic acid side chain that also extends duration)'"`UNIQ--ref-00001375-QINU`"'
~60-87% (oral; high and more consistent than codeine or hydrocodone, making efficacy less CYP2D6-genotype-dependent)'"`UNIQ--ref-0000001E-QINU`"'
~60-87% oxycodone (high and predictable, less CYP-genotype-dependent than codeine or hydrocodone); 85-98% acetaminophen'"`UNIQ--ref-000014E3-QINU`"'
~60–70% (oral)
~62%
~63% (oral)'"`UNIQ--ref-00000532-QINU`"'
~63% (oral; extensive first-pass)'"`UNIQ--ref-00000015-QINU`"'
~64% (oral)'"`UNIQ--ref-00000016-QINU`"'
~64% (oral; not significantly affected by food)'"`UNIQ--ref-0000015F-QINU`"'
~64% from SC depot'"`UNIQ--ref-00001104-QINU`"'
~64-90% (oral; increases at higher doses and with multi-day dosing)'"`UNIQ--ref-000008E9-QINU`"'
~65% (oral)'"`UNIQ--ref-0000001E-QINU`"'
~65% (oral)'"`UNIQ--ref-00000784-QINU`"'
~65% (oral)'"`UNIQ--ref-00000AB1-QINU`"'
~65% (oral)'"`UNIQ--ref-000013F6-QINU`"'
~67% (oral)'"`UNIQ--ref-00000B26-QINU`"'
~70% (oral)'"`UNIQ--ref-0000001B-QINU`"'
~70% (oral)'"`UNIQ--ref-00000022-QINU`"'
~70% (oral)'"`UNIQ--ref-000008C5-QINU`"'
~70% (oral; bioavailability and absorption are improved with food)'"`UNIQ--ref-00000355-QINU`"'
~70% (oral; reduced by divalent cations — antacids, iron, calcium, dairy)'"`UNIQ--ref-00000939-QINU`"'
~70-85% (oral)'"`UNIQ--ref-00000027-QINU`"'
~70-90% at typical doses; saturable at high doses (>500 mg)
~72% (with food); much lower fasting (~36%)
~72% from SC depot'"`UNIQ--ref-00001480-QINU`"'
~72% oral; ~85% smoked'"`UNIQ--ref-00000066-QINU`"'
~75%
~75% (IR, rises with multi-dose administration due to saturable first-pass)'"`UNIQ--ref-0000001E-QINU`"'
~75% (oral, as the active carboxylate after hepatic esterase activation)'"`UNIQ--ref-00000E95-QINU`"'
~75% (oral; absorption improved with fat-containing meal)
~75% (oral; fat-soluble, absorption requires intact biliary/lipid digestion)'"`UNIQ--ref-00000331-QINU`"'
~75-85% (oral); ~60% (transdermal at steady state)'"`UNIQ--ref-00000027-QINU`"'
~75–90% (oral)
~77% (oral; not affected by food or antacids)'"`UNIQ--ref-0000011E-QINU`"'
~78% (oral; high-fat meal modestly reduces but is not clinically significant)'"`UNIQ--ref-00000553-QINU`"'
~80% (oral)'"`UNIQ--ref-0000001B-QINU`"'
~80% (oral)'"`UNIQ--ref-0000001E-QINU`"'
~80% (oral)'"`UNIQ--ref-00000029-QINU`"'
~80% (oral)'"`UNIQ--ref-00000310-QINU`"'
~80% (oral)'"`UNIQ--ref-00000BEC-QINU`"'
~80% (oral)'"`UNIQ--ref-00000E2C-QINU`"'
~80% (oral; predictable absorption — a substantive practical advantage over furosemide whose oral absorption is 10-100% variable)'"`UNIQ--ref-00000B47-QINU`"'
~80% (oral; reduced by significant first-pass)'"`UNIQ--ref-00000EFA-QINU`"'
~80-100% (oral)'"`UNIQ--ref-00000027-QINU`"'
~80-100% with food at 15-20 mg doses (10 mg dose: ~80% without food); '''must be taken with food''' at therapeutic doses'"`UNIQ--ref-00000514-QINU`"'
~80-95% (oral; more reliable than furosemide, comparable to torsemide)'"`UNIQ--ref-00000DE4-QINU`"'
~80-99% (oral)'"`UNIQ--ref-00000868-QINU`"'
~82%
~82% SC
~85-90% (oral; not significantly affected by food)'"`UNIQ--ref-00000955-QINU`"'
~85-98% (oral)'"`UNIQ--ref-000006A6-QINU`"'
~87% (oral)'"`UNIQ--ref-00000024-QINU`"'
~87% (oral)'"`UNIQ--ref-00000766-QINU`"'
~89% (oral)'"`UNIQ--ref-00000021-QINU`"'
~90% (low first-pass)
~90% (oral)'"`UNIQ--ref-00000018-QINU`"'
~90% (oral)'"`UNIQ--ref-00000024-QINU`"'
~90% (oral)'"`UNIQ--ref-00000027-QINU`"'
~90% (oral)'"`UNIQ--ref-00000DFF-QINU`"'
~90% (oral)'"`UNIQ--ref-00001140-QINU`"'
~90% (oral)'"`UNIQ--ref-00001443-QINU`"'
~90% (oral, low first-pass)'"`UNIQ--ref-0000001C-QINU`"'
~90% (oral; food increases absorption)'"`UNIQ--ref-000008A4-QINU`"'
~90% (oral; not affected by food but reduced by divalent cations)'"`UNIQ--ref-00000D83-QINU`"'
~93% (oral); ~90% (rectal)'"`UNIQ--ref-00000027-QINU`"'
~93% (oral)'"`UNIQ--ref-00000ED4-QINU`"'
~95% (oral)'"`UNIQ--ref-0000001F-QINU`"'
~95% (oral)'"`UNIQ--ref-0000002A-QINU`"'
~95% (oral)'"`UNIQ--ref-0000149E-QINU`"'
~95% (oral)'"`UNIQ--ref-000014C4-QINU`"'
~95% (oral; reduced by dairy, antacids, iron via divalent-cation chelation, though less than for tetracycline itself)'"`UNIQ--ref-0000047E-QINU`"'
~96% (oral)'"`UNIQ--ref-00000AD2-QINU`"'
~96% after red blood cell hydrolytic cleavage releases dextroamphetamine'"`UNIQ--ref-00000018-QINU`"'
~98% (oral)'"`UNIQ--ref-00000026-QINU`"'
~99% (caffeine)
~99% (oral)'"`UNIQ--ref-0000002A-QINU`"'
~99% (oral; matched 1:1 IV-to-PO conversion)'"`UNIQ--ref-00000CF6-QINU`"'
≥90% (linear pharmacokinetics, distinguishing it favorably from gabapentin's saturable LAT-1 absorption)'"`UNIQ--ref-00000027-QINU`"'
Search
pregnancy:
None
(1)
legal:
[[USLegal:DEA Schedule II|Schedule II]] controlled substance in US (rescheduled from Schedule III in 1978). No accepted medical use. UN Convention on Psychotropic Substances Schedule II internationally.'"`UNIQ--ref-00000067-QINU`"' (1)
Error in "where" parameter: the string "--" cannot be used within #cargo_query.
There are no results for this report.
Search
Search
Drilldown: Medicines
Add topic
& routes:
IM 
generic:
starting dose: (Click arrow to add another value)